Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)
This study is currently recruiting participants.
Verified October 2017 by Washington University School of Medicine
Sponsor:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01760005
First Posted: January 3, 2013
Last Update Posted: October 5, 2017
Collaborators:
Eli Lilly and Company
Hoffmann-La Roche
Alzheimer's Association
National Institute on Aging (NIA)
Avid Radiopharmaceuticals
Accelerating Medicines Partnership (AMP)
Janssen Research and Development
Information provided by (Responsible Party):
Washington University School of Medicine
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.
| Condition | Intervention | Phase |
|---|---|---|
| Alzheimers Disease Dementia Alzheimers Disease, Familial | Drug: Gantenerumab Drug: Solanezumab Drug: Matching Placebo (Gantenerumab) Drug: Matching Placebo (Solanezumab) Drug: JNJ-54861911 Drug: Matching Placebo (JNJ-54861911) | Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease |
Resource links provided by NLM:
Further study details as provided by Washington University School of Medicine:
Primary Outcome Measures:
- Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by change in the DIAN-TU cognitive composite score. [ Time Frame: Baseline and Weeks 52, 104, 156, and 208 ]
Secondary Outcome Measures:
- Gantenerumab: Cerebral amyloid imaging using [11C]PiB-PET. [ Time Frame: Baseline and Weeks 52, 104, and 208 ]
- Solanezumab: Total Abeta 1-42 (Aβ42) in CSF. [ Time Frame: Baseline, Week 104 ]
- JNJ-54861911: CSF amyloid-beta peptide concentration as measured by Abeta 1-42 (Aβ42) in CSF. [ Time Frame: Baseline, Week 208 ]
- Change from Baseline in Clinical Measures [ Time Frame: Baseline, week 208 ]
- Clinical Dementia Rating (CDR), including CDR sum of boxes (CDR-SB) and clinician's diagnostic assessment
- Geriatric Depression Scale (GDS)
- Neuropsychiatric Inventory Questionnaire (NPI-Q)
- Functional Assessment Questionnaire (FAQ)
- Mini Mental Status Exam (MMSE)
- Change from Baseline in Cognitive Measures [ Time Frame: Baseline, week 208 ]
- International Shopping List Test (12-Item Word List Learning): 3 learning trials, Immediate Recall, 30-min Delayed Recall (CogState)
- Groton Maze Learning Test: Timed Chase Task, 5 learning Trials, Immediate Recall, 30-min Delayed Recall (CogState)
- Cogstate Detection Task
- Cogstate Identification Test
- Cogstate One Card Learning Test
- Cogstate One-Back (OBK) Task
- Behavioral Pattern Separation Object Task
- Memory Complaint Questionnaire (MAC-Q)
- Trails A & B
- Wechsler Memory Scale - Revised (WMS-R) Digit Span
- Wechsler Adult Intelligence Scale - Revised (WAIS-R) Digit-Symbol Substitution Test
- Raven's Progressive Matrices (Set A)
- Category Fluency (Animals & Vegetables)
- Wechsler Memory Scale Logical Memory I Paragraph Memory (Immediate & Delayed Recall)
Other Outcome Measures:
- Safety and Tolerability Outcome Measures [ Time Frame: Baseline, week 208 ]
- Neurological findings
- Laboratory test results
- ECG findings
- Safety MRIs
| Estimated Enrollment: | 438 |
| Study Start Date: | December 2012 |
| Estimated Study Completion Date: | December 2023 |
| Estimated Primary Completion Date: | September 2023 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Gantenerumab |
Drug: Gantenerumab
Subcutaneously every 4 weeks at escalating doses
Other Name: RO4909832
|
| Experimental: Solanezumab |
Drug: Solanezumab
Intravenous infusion every 4 weeks at escalating doses
Other Name: LY2062430
|
| Placebo Comparator: Matching placebo (Gantenerumab) |
Drug: Matching Placebo (Gantenerumab)
Subcutaneous injection of placebo every 4 weeks
|
| Placebo Comparator: Matching Placebo (Solanezumab) |
Drug: Matching Placebo (Solanezumab)
Intravenous infusion of placebo every 4 weeks
|
| Experimental: JNJ-54861911 |
Drug: JNJ-54861911
25 mg daily oral tablet
|
| Placebo Comparator: Matching Placebo (JNJ-54861911) |
Drug: Matching Placebo (JNJ-54861911)
Daily oral placebo tablet
|
Show Detailed Description
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Between 18-80 years of age
- Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have a 50% chance of having an autosomal dominant Alzheimer's disease (ADAD) mutation (e.g. parent or sibling with a known AD-causing mutation)
- Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset
- Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)
- Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning
- Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.
- For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide).
- Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
- Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion.
Exclusion Criteria:
- History or presence of brain MRI scans indicative of any other significant abnormality
- Alcohol or drug dependence currently or within the past 1 year
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan.
- History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
- Anticoagulants except low dose (≤ 325 mg) aspirin.
- Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
- Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
- Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.
- JNJ-54861911 study arm only: Hypopigmentation abnormality of the skin such as vitiligo, other than small localized findings, at baseline dermatological test.
- JNJ-54861911 study arm only: Subjects with the APP Swedish Mutation
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01760005
Contacts
| Contact: Ellen Ziegemeier, MA | 844-DIANEXR (342-6397) | dianexr@neuro.wustl.edu | |
| Contact: Mary Downey-Jones | 844-DIANEXR (342-6397) | dianexr@neuro.wustl.edu |
Show 26 Study Locations
Sponsors and Collaborators
Washington University School of Medicine
Eli Lilly and Company
Hoffmann-La Roche
Alzheimer's Association
National Institute on Aging (NIA)
Avid Radiopharmaceuticals
Accelerating Medicines Partnership (AMP)
Janssen Research and Development
Investigators
| Study Director: | Randall J Bateman, MD | Washington University School of Medicine |
More Information
Additional Information:
Publications:
| Responsible Party: | Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT01760005 History of Changes |
| Other Study ID Numbers: |
DIAN-TU-001 The Alzheimer's Association ( Other Grant/Funding Number: DIAN TTU-12-243040 ) U01AG042791 ( U.S. NIH Grant/Contract ) 2013-000307-17 ( EudraCT Number ) R01AG046179 ( U.S. NIH Grant/Contract ) REec-2014-0817 ( Registry Identifier: Spanish Clinical Studies Registry ) The Alzheimer's Association ( Other Grant/Funding Number: DIAN-TU Tau-15-347219 ) The Alzheimer's Association ( Other Grant/Funding Number: DIAN-TU NG-16-434362 ) R56AG053267 ( U.S. NIH Grant/Contract ) GHR Foundation ( Other Grant/Funding Number: File 4401 ) |
| First Submitted: | December 26, 2012 |
| First Posted: | January 3, 2013 |
| Last Update Posted: | October 5, 2017 |
| Last Verified: | October 2017 |
Keywords provided by Washington University School of Medicine:
|
Alzheimer's Alzheimer's Disease Dementia Mutation Genetic Mutation Dominantly Inherited Alzheimer's Disease |
Dominantly Inherited Alzheimer's Network Autosomal Dominant Alzheimer's Disease Early Onset Alzheimer's Disease DIAN DIAN-TU DIAN TU |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies |
Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs |